Physician profile
Alexander Lim
NPI 1184157539
$1,784.24
in general payments reported to CMS, 2019-2025
23 companies · $67.34 in 2025
The $67.34 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.59 · 2022: $235 · 2023: $689 · 2024: $770 · 2025: $67.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,426 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,425.99 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $232.77 | 2023-2024 | Calquence, Enhertu, Imfinzi |
| Seagen INC. | $218.85 | 2023 | Padcev |
| Novartis Pharmaceuticals Corporation | $215.57 | 2023-2025 | |
| Genentech USA, INC. | $157.63 | 2023-2024 | Lunsumio, Columvi, Alecensa |
| Inari Medical, INC. | $123.02 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| E.R. Squibb & Sons, L.L.C. | $118.12 | 2022 | |
| Amgen INC. | $116.55 | 2022 | |
| Janssen Biotech, INC. | $109.54 | 2024 | Rybrevant, Talvey, Tecvayli |
| Beigene USA, INC. | $90.52 | 2024 | Brukinsa |
| Pfizer INC. | $75.49 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.01 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $36.86 | 2023 | Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $34.40 | 2023-2024 | Alunbrig, Fruzaqla |
| Tempus Ai, INC | $33.87 | 2024 | |
| Abbvie INC. | $26.66 | 2023-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $23.59 | 2019 | |
| Daiichi Sankyo INC. | $21.77 | 2025 | Enhertu |
| Adc Therapeutics America, INC. | $19.82 | 2024 | |
| Genzyme Corporation | $19.37 | 2024 | |
| Celgene Corporation | $16.35 | 2024 | |
| Eisai INC. | $15.70 | 2024 | |
| Stemline Therapeutics INC. | $15.19 | 2023 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $13.59 | 2024 | Somatuline Depot, Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.